Cablevision’s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

Bookmark and Share

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Foundation provides the best and brightest minds with the resources and flexibility to pursue science of the highest quality. To date, we have committed more than $22 million for the study of pancreatic cancer research. What began as a small but dedicated community of pancreatic cancer researchers is now a critical mass of investigators with shared interest in the disease.

By Year

2010

University of Texas M.D. Anderson Cancer Center
Rosa F. Hwang, M.D.
Wnt signaling in pancreatic cancer associated stroma

Columbia University
Thomas Ludwig, Ph.D.
The role of PALB2/FANCN in the development of pancreatic cancers

Johns Hopkins University
Akhilesh Pandey, M.D., Ph.D.
Kinome profiling to identify novel therapeutic targets in pancreatic cancer

Rockefeller University
Ralph Steinman, M.D.
Immunotherapy of pancreatic cancer by targeting mesothelin to activated dendritic cells in vivo

2009

Johns Hopkins University
Nita Ahuja, M.D.
Aberrant Hypermethylation of CpG Island Promoters in Pancreatic Cancer: Constructing a Hypermethylome

University of California, San Francisco
Allan Balmain, Ph.D.
Therapeutic Approaches to Pancreatic Cancer Based on K-Ras Isoform 4A Expression in Stem Cells

Fred Hutchinson Cancer Research Center
Sunil R. Hingorani, M.D., Ph.D.
Oncogenic K-Ras as a Therapeutic Target for Pancreas Cancer

Johns Hopkins University
Allison Klein, Ph.D.
Identification of Pancreatic Cancer Susceptibility Genes

University of Michigan Medical School
Chandan Kumar, Ph.D.
Discovery of Recurrent Gene Fusions in Pancreatic Cancer using High-Throughput Sequencing

Johns Hopkins University School of Medicine
Joshua Mendell, M.D., Ph.D.
Ras-regulated microRNAs in Pancreatic Cancer

Massachusetts General Hospital
Jeffrey Settleman, Ph.D.
Identification and Validation of Novel Therapeutics Targets for K-Ras-mutant Pancreatic Cancer

Ohio State University
Thomas D. Schmittgen, Ph.D.
MicroRNA Profiling in Serum of Pancreatic Adenocarcinoma Patients
*Supported by a generous donation from the Michael Rolfe Pancreatic Cancer Foundation

The Johns Hopkins University School of Medicine
Bert Vogelstein, M.D.
Development of Novel Diagnostic Approaches for the Early Detection of Pancreatic Neoplasms

Top of Page

2008

Columbia University
Timothy Wang, M.D.
Development of An Inflammation-Based Pancreatic Cancer Model and Exploration of the Origins of Pancreatic Cancer
Supported by a generous donation from The Lefkofsky Family Foundation

Dana-Farber Cancer Institute
James DeCaprio, M.D.
The Pancreatic Cancer Biomarker Initiative

Dartmouth College
Catherine Carrière, Ph.D.
Adult Pancreatic Progenitor Cells as Targets of Oncogenic Events

Johns Hopkins Medical Institutions
Michael Goggins, M.D.
Novel Strategies and Technologies for Identifying Familial Pancreatic Cancer Genes

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Targeting the Herpes Virus Entry Mediator (HVEM) As A Novel Therapeutic Strategy in Pancreatic Cancer

Massachusetts General Hospital
Kimberly A. Kelly, Ph.D.
Plectin-1 As A Biomarker for the Early Detection of Pancreatic Ductal Adenocarcinoma

Mayo Clinic College of Medicine
Fergus J. Couch, Ph.D.
Genetic Epidemiology of Novel Pancreatic Cancer Susceptibility Genes

The Canary Foundation
Brad Nelson, Ph.D.
The Pancreatic Cancer Biomarker Initiative

University of California at San Francisco
James D. Marks, M.D., Ph.D.
The Pancreatic Cancer Biomarker Initiative

Van Andel Research Institute
Brian B. Cao, M.D.
The Pancreatic Cancer Biomarker Initiative

Top of Page

2007

Dana-Farber Cancer Institute
David Frank, M.D., Ph.D.
Inhibition of STAT3 in the Targeted Therapy of Pancreatic Cancer

Johns Hopkins Medical Institutions 
James Eshleman, M.D., Ph.D.
Pancreatic Cancer Tumor Suppressor Gene Discovery using RNAi

Johns Hopkins Medical Institutions 
Anirban Maitra, MBBS 
Synergistic Targeting of the Apoptotic Machinery in Pancreatic Cancer

Johns Hopkins Medical Institutions
Bert Vogelstein, M.D.
Sequencing the Pancreatic Cancer Genome

Purdue University 
Stephen F. Konieczny, Ph.D. 
Mist 1 Kras G12D Generated Pancreatic Cancer

Salk Institute for Biological Studies 
Inder M. Verma, Ph.D. 
A Novel Mouse Model of Pancreatic Cancer Using Lentiviral Vectors

Samuel Lunenfeld Research Institute 
Steven Gallinger, M.D.
Characterization of Germline DNA Copy Number Variation in Familial Pancreas Cancer

University of California at San Francisco Comprehensive Cancer Center 
Martin McMahon, Ph.D.
Targeting Kinases to Overcome Gemcitabine Resistance in Pancreatic Carcinoma

Top of Page

2006

Cambridge Research Institute
David Tuveson, M.D., Ph.D. 
Novel Anti-K-ras Strategies in Ductal Pancreatic Cancer

Georgetown University Medical Center 
Anna Riegel, Ph.D. 
The Role of the Nuclear Receptor Coactivator AIB1in the Early Preneoplastic Stages of Pancreatic Cancer

Johns Hopkins Medical Institutions
Marcia Canto, M.D. 
Screening for Early Pancreatic Neoplasia: A Multi-Center Study

Johns Hopkins Medical Institutions
Elizabeth Jaffee, M.D.
 Functional Genomic Approach to Identify Genes that are Pancreatic Cancer Immune Targets

Johns Hopkins Medical Institutions
Steven D. Leach, M.D.
 High-Throughput, In-Vivo Screening for Novel Pancreatic Cancer Drugs Using the Zebrafish System

Johns Hopkins Medical Institutions 
Joshua Mendell, M.D., Ph.D. 
The Role of MicroRNAs in the Pathogenesis of Pancreatic Cancer

Technical University of Munich
Roland Schmid, M.D.
Jens T. Svieke, M.D.
The Role of Notch Signaling in Pancreatic Cancer Development

University of Michigan Medical Center 
Diane Simeone, M.D. 
Pancreatic Cancer Stem Cells

University of Texas M.D. Anderson Cancer Center
George Halder, Ph.D. 
A Novel Genetic System to Identify Ideal Cancer Drug Targets in Pancreatic Cancer

University of Utah 
Lewis Charles Murtaugh, Ph.D. 
Interdependence of Notch and Kras Signaling in Pancreatic Tumorigenesis

Top of Page

2005

Johns Hopkins Medical Institutions
Steven Leach, M.D.
Zebrafish Model of Early Pancreatic Cancer

Massachusetts General Hospital
Kimberly Kelly, Ph.D.
Development of Molecular Imaging Agents for Early Detection of Pancreatic Cancer

Massachusetts General Hospital
Sarah Thayer, M.D., Ph.D.
Shh Links Chronic Inflammatory Injury to Pancreatic Carcinogenesis

Mayo Clinic
Amy Tang, Ph.D.
SIAH:  A Novel Biomarker of Pancreatic Cancer Progression and Therapeutic Implications

Technical University of Munich
Roland Schmid, M.D.
The Role of Notch Signaling in the Kras Mouse Model of Pancreatic Cancer

Top of Page

2004

Dana-Farber Cancer Institute
Nabeel  Bardeesy, Ph.D.
Pancreatic Cancer Models for The Identification of Biomarkers and Tumor Maintenance Programs

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Hedgehog Inhibitors of Pancreatic Cancer

Mayo Clinic College of Medicine
Janet Olsen, Ph.D.
Identification of Early Stage Pancreatic Cancer Biomarkers using LC-Dual ESI-FT-ICR Mass Spectrometry

Mayo Clinic at Rochester
Suresh T. Chari, M.D.
Serum Proteomics of Pancreatic Cancer- Induced Diabetes
 
Meharry Medical College and Vanderbilt University
Ana M. Grau, M.D.
Role of Rhob in Tumorigenesis and Metastasis In Pancreatic Cancer

Memorial Sloan-Kettering Cancer Center
Richard N. Kolesnick, M.D.
Development of KSR Phosphorothioate Antisense Oligonucleotides in the Treatment of Human Pancreatic Cancer

Mt. Sinai Hospital, Toronto / Samuel Lunenfeld Research Institute
Steven  Gallinger, M.D.
A Novel Pancreatic Cancer Tumor Suppressor Candidate Gene

New York University School of Medicine
Daniel  Meruelo, Ph.D.
Imaging-Assisted Design of Viral Vectors to Eradicate Metastatic Pancreatic Cancer

Northwestern University
Paul Grippo, Ph.D.
Dual Targeting of Mutant Kras And Muchin1 in Mice That Develop Human Like Panins

Stanford University School of Medicine
Jonathan  Pollack, M.D., Ph.D.
Locating Novel Pancreatic Cancer Genes with DNA Microarrays

State University of New York at Stony Brook
Dafna  Bar-Sagi, Ph.D.
Analysis of Pancreatic Ductal Adenocarcinoma Progression in a Mouse Model of Hereditary Pancreatitis

University of Alabama at Birmingham
Pierre L. Triozzi, M.D.
ErbB Receptor Immunotherapy

University of California at San Francisco
Matthias  Hebrok, Ph.D.
Embryonic Signaling Pathways in Pancreatic Cancer

University of Michigan Medical Center
Diane M. Simeone, M.D.
Development and Validation of Novel Biomarkers for Early Pancreatic Cancer Detection

Top of Page

2003

Aston University, United Kingdom
Michael Tisdale, Dsc., Ph.D.
Cloning and Expression of a Muscle Receptor for a Cancer Cachectic Factor

Cold Spring Harbor Laboratory  
Robert Lucito, Ph.D.  
Genomic Analysis of Pancreatic Cancer Using DNA Microarrays

Columbia University, College of Physicians and Surgeons
Paul B. Fisher, Ph.D.
Exploiting Defects in Molecular Circuitry to Selectively Kill Pancreatic Cancer Cells

Dana-Farber Cancer Institute
Nabeel Bardeesy, Ph.D.
Preclinical Model System for Kras Directed Pancreatic Tumor Maintenance and Biomarker Identification

Dana-Farber Cancer Institute/ Harvard Medical School
Lynda Chin, M.D.
Comprehensive View of Pancreatic Cancer Oncogenomics

Dana-Farber Cancer Institute 
Charles Fuchs, M.D., M.P.H.
Prospective Study of Pancreatic Cancer Pathogenesis

Dana-Farber Cancer Institute / Harvard Medical School
Muneesh Tewari, M.D., Ph.D.
A Synthetic Lethal Screen to Discover Tumor-Selective Drug Targets in Pancreatic Cancer

Johns Hopkins Medical Institutions
Michael Goggins, M.D.
Proteomic Profiles of Pancreatic Juice for the Early Detection of Pancreatic Cancer

Johns Hopkins Medical Institutions
Christine Iacobuzio-Donahue, M.D., Ph.D.
Towards a Comprehensive Understanding of Pancreas Cancer Through Gene Expression Profiling

Johns Hopkins Medical Institutions
Gloria Su, Ph.D.
Identification of Tissue-Specific Promoters for Ductal Epithelium of Pancreas Using SAGE Libraries

Massachusetts General Hospital/ Harvard Medical School
Sarah Thayer, M.D., Ph.D.
To Characterize the Contribution of Sonic Hedgehog to Pancreatic Neoplasia

Memorial Sloan-Kettering Cancer Center
Gary K. Schwartz, M.D.
Clinical Development of Flavorpiridol for Patients With Locally Advanced and Metastatic Pancreatic Cancer

Stanford University School of Medicine
Jonathan R. Pollack, M.D., Ph.D.
Locating Novel Pancreatic Cancer Genes With DNA Microarrays

University of Washington
Teresa Brentnall, M.D.
Discovery of a Familial Pancreatic Cancer Gene

Top of Page

2002

Columbia University
Argiris Efstratiadis, M.D., Ph.D.
Development of a Mouse Model of Pancreatic Cancer

Johns Hopkins Medical Institutions
Anirban Maitra, MBBS
Genetic Basis of Familial Pancreatic Cancer: A Novel Approach Using Whole Genome Conversion and High-Throughput Oligonucleotide Microarrays

Mayo Clinic at Rochester
Raul Urrutia, M.D.
Role of Novel Sp1-like Proteins in the Transcriptional Silencing Carcinogen-activating Enzymes in Exocrine Pancreatic Cells

Stanford University
Albert Koong, M.D., Ph.D.
Selective Modulators of Protein Kinase C Activity as a Novel Class of Hypoxia Cell Cytotoxins in Human Pancreatic Cancer

Stanford University
Anson W. Lowe, M.D.
Characterizing the Gene-expression Profile of Human Pancreatic Cancers

University of California at Davis Cancer Center
Richard Bold, M.D.
Anti-apoptotic Signaling through the AKT Kinase in Pancreatic Cancer

University of California at San Francisco Comprehensive Cancer Center
Martin McMahon, Ph.D.
A Systematic, Genome-Wide Analysis of Gene Copy Number Alteration in Pancreatic Cancer Cells by Array CGH

University of Michigan
Craig Logsdon, Ph.D.
The Role of ATDC in Radioresistance of Pancreatic Adenocarcinoma

University of Nebraska Medical Center/Eppley Cancer Research Institute
Michel Ouellette, Ph.D.
In-Vitro Models of Pancreatic Cancer Development

University of North Carolina at Chapel Hill
Adrienne D. Cox, Ph.D.
Functional Consequences of Oncogenically Mutated Kras in Pancreatic Cancer

University of Pittsburgh Cancer Institute
Katherine Pogue-Geile, Ph.D.
Functional Identification of Pancreatic Tumor Suppressor Genes

University of Pittsburgh Cancer Institute
Ramesh K. Ramanathan, M.D.
Co-Principal Investigator: Olivera Finn, Ph.D.
Phase I/II Study of a MUC-1 Pulsed Dendritic Cell Vaccine In Resected Pancreatic and Biliary Cancers

University of Texas M.D. Anderson Cancer Center
Lee Ellis, M.D.
Role of Neuropilin-1 in Pancreatic Cancer Growth and Angiogenesis

Top of Page

2001

Aston University, United Kingdom
Michael J. Tisdale, DSc., Ph.D.
Mechanism of Muscle Protein Catabolism in Cancer Cachexia

Beth Israel Deaconess Medical Center
Hava Avraham Ph.D.
Studies of CHK Kinase in Pancreatic Cancer Cells

Harvard School of Public Health
Eric J. Duell, Ph.D.
Gene-Environment Interactions in Pancreatic Adenocarcinoma

Johns Hopkins Medical Institutions
Michael G. Goggins, M.D.
Proteomic Profiles of Pancreatic Cancer

Johns Hopkins Medical Institutions
Gloria Su, Ph.D.
Mouse Models for Human Pancreatic Cancer

Johns Hopkins Medical Institutions
Steven D. Leach, M.D.
Notch Signaling in Pancreatic Cancer Precursors

Mayo Clinic at Rochester
Gloria M. Peterson, Ph.D.
Genetic Epidemiology of Pancreatic Cancer

Memorial Sloan-Kettering Cancer Center
Yuman Fong, M.D.
Synergy of Herpes Viruses with Chemotherapy or Immunotherapy in the Treatment of Pancreatic Cancer

SUNY Downstate Medical Center
Josef Michl, M.D.
Matthew R. Pincus, M.D., Ph.D.
Novel Methods in the Diagnosis and Treatment of Pancreatic Cancer

University of Alabama at Birmingham
David T. Curiel, M.D.
Pancreatic Carcinoma Specific Replicative Adenoviral Agent

University of Pittsburgh
David C. Whitcomb, M.D., Ph.D.
Identify Genes Which are Only Expressed in Pancreatic Cancer Cells

University of Texas M.D. Anderson Cancer Center
Shrikanth A. G. Reddy, Ph.D.
AP-1 and Ras Signaling in Pancreatic Cancer Cells

Top of Page

1998 – 2000

Duke University Medical Center
Douglas Tyler, M.D.
Immunotherapy of Pancreatic Cancer Using Dendritic Cells Pulsed with Antigen in the Form of Amplified Total Tumor R

Johns Hopkins Medical Institutions 
Michael Goggins, M.D.
Detect Early Symptomless Pancreatic Cancer

Johns Hopkins Medical Institutions
Constance Griffin, M.D. 
Chromosome Analysis in Patients with Familial Pancreatic Cancer

Johns Hopkins Medical Institutions 
Elizabeth Jaffee, M.D. 
A Phase II Study of an Allogeneic Gm-CSF Secreting Pancreatic Tumor Vaccine

University of Texas M.D. Anderson Cancer Center 
Keping Xie, M.D., Ph.D.
Control of Pancreatic Cancer Metastasis by Modulating Tumor-associated Nitric Oxide Production

Creighton University School of Medicine 
Thomas Adrian, Ph.D.
LOX Inhibitors for Pancreatic Cancer Treatment and Prevention

University of California at San Francisco Comprehensive Cancer Center 
Margaret Tempero, M.D. 
Optimizing Therapy for Pancreatic Adenocarcinoma with TALL-104 Cells

University of Texas at San Antonio 
James Freeman, Ph.D. 
TGF-B Type II Receptor Gene as a Target for the Antitumor Effect of Farnesyltransferace Inhibitors in Pancreatic Cancer

University of Texas M.D. Anderson Cancer Center 
Robert Radinsky, Ph.D. 
Blocking Tumor Growth Factor Receptors in Pancreatic Tumor Cells

Top of Page


“As a result of Lustgarten Foundation funding, we were able to produce enough vaccine to test our potential therapy in pancreatic cancer patients. Without this funding, we would not have been able to conduct this trial.”
-  Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions

Join Now

The Lustgarten Foundation
1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303
©2009 Lustgarten Foundation